Saturday 17 October 2026
Export ANEB’s income statement to Excel — free account
Anebulo Pharmaceuticals, Inc.
ANEB Healthcare Biotechnology
In the quarter to December 2025, EPS grew 44.4% and free cash flow grew 6.58%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.00
0.31
−100.00%
Follow ANEB
| Jun '25 | Jun '24 | Jun '23 | Jun '22 | Jun '21 | Jun '20 | Jun '17 | |
|---|---|---|---|---|---|---|---|
Current Ratio |
24.53 | 13.46 | 10.92 | 30.40 | 89.63 | 13.53 | — |
Net Debt/EBITDA |
1.32 | 0.38 | 0.95 | 2.13 | 5.53 | 17.45 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.75 | 0.99 | 0.83 | 0.80 | 0.13 | 0.86 | — |
Capex/Depreciation |
0.00 | 0.00 | — | — | — | — | — |
Interest Coverage |
(24.15) | (54.95) | (127.53) | (935.78) | (306.25) | (133.38) | — |
| (109.69%) | (113.80%) | (91.41%) | (37.42%) | (362.14%) | (1.64%) | — | |
| (104.63%) | (104.19%) | (86.11%) | (36.66%) | (311.65%) | (11.53%) | — | |
ROIC |
(19,215.63%) | (722.96%) | 0.00% | (823.59%) | (158.37%) | 0.00% | — |
Return on Tangible Assets |
(73.94%) | (252.56%) | (110.67%) | (45.30%) | (179.62%) | (6.23%) | — |
Average Days of Receivables |
0.00 | — | — | — | — | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(0.19) | (0.31) | (0.39) | (0.23) | (0.36) | (0.01) | — |
Cash per Share |
0.34 | 0.12 | 0.45 | 0.62 | 1.47 | 0.25 | — |
Shareholders Equity per Share |
0.34 | 0.15 | 0.42 | 0.65 | 1.57 | (0.01) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.34 | 0.15 | 0.42 | 0.65 | 1.57 | (0.01) | — |
Free Cash Flow |
(6.35) | (8.09) | (9.68) | (5.44) | (4.87) | (0.15) | — |
Working Capital |
11.47 | 3.25 | 10.60 | 15.07 | 21.41 | 2.80 | — |
Net Current Asset Value |
11.47 | 3.25 | 10.60 | 15.07 | 21.41 | (0.17) | — |
| Other line items | |||||||
Quick Ratio |
23.99 | 11.87 | 10.52 | 28.39 | 82.72 | 13.53 | — |
Depreciation/Fixed assets |
0.00 | 0.00 | — | — | — | — | — |
Cash ROIC |
(27.27%) | (117.14%) | (44.32%) | (18.36%) | (11.77%) | (5.28%) | — |
Accounts Receivable Turnover |
0.00 | — | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.19) | (0.31) | (0.39) | (0.23) | (0.36) | (0.01) | — |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
0.04 | — | — | — | — | — | — |
Average Payables |
0.19 | 0.35 | 0.46 | 0.25 | — | — | — |
Average Assets |
8.11 | 7.87 | 13.62 | 18.62 | 12.34 | 1.51 | — |
Average Common Equity |
7.74 | 7.21 | 12.83 | 18.24 | 10.62 | 10.62 | — |
Columns are period end dates